What is in a name; and why does the nomenclature of one disease, primary biliary cirrhosis, cause such contention that a proposed name change by those deeply committed to the advancement of its understanding and management stimulate huge debate?
This is a preview of subscription content, log in via an institution to check access.
References
Trivedi, P. J. et al. Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response. J. Hepatol. 60, 1249–1258 (2014).
Lammers, W. J. et al. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology http://dx.doi.org/10.1053/j.gastro.2015.07.061.
Carbone, M. et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastroenterology 144, 560–569 (2013).
Sherlock, S. & Scheuer, P. J. The presentation and diagnosis of 100 patients with primary biliary cirrhosis. N. Engl. J. Med. 289, 674–678 (1973).
Beuers, U. et al. Changing nomenclature for PBC: from 'cirrhosis' to 'cholangitis'. Hepatology http://dx.doi.org/10.1002/hep.28140.
Degott, C. et al. Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. Hepatology 29, 1007–1012 (1999).
Trivedi, P. J., Corpechot, C., Pares, A. & Hirschfield, G. M. Risk Stratification in autoimmune cholestatic liver diseases: opportunities for clinicians and trialists. Hepatology http://dx.doi.org/10.1002/hep.28128.
Hirschfield, G. M., Thain, C., Walmsley, M., Brownlee, A. & Jones, D. E. Liver disease in the UK. Lancet 385, 503 (2015).
Corpechot, C. et al. Smoking as an independent risk factor of liver fibrosis in primary biliary cirrhosis. J. Hepatol. 56, 218–224 (2012).
Hirschfield, G. M. et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 148, 751–761 (2015).
Acknowledgements
P.J.T. has received funding from the NIHR Birmingham Liver Biomedical Research Unit and is in receipt of a Wellcome Trust funded Clinical Research Fellowship. G.M.H. has received funding from the NIHR Birmingham Liver Biomedical Research Unit and is a co-investigator for UK-PBC supported by a Stratified Medicine Award from the UK Medical Research Council. The views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR, or the Department of Health.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Trivedi, P., Hirschfield, G. Renaming primary biliary cirrhosis—clarity or confusion?. Nat Rev Gastroenterol Hepatol 12, 678–679 (2015). https://doi.org/10.1038/nrgastro.2015.187
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2015.187
- Springer Nature Limited
This article is cited by
-
Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis
Journal of Gastroenterology (2022)
-
Rebranding Gout: Could a Name Change for Gout Improve Adherence to Urate-Lowering Therapy?
Therapeutic Innovation & Regulatory Science (2021)
-
Diagnosis and Management of Primary Biliary Cholangitis
American Journal of Gastroenterology (2019)
-
Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome
American Journal of Gastroenterology (2018)